Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alseres Pharmaceuticals, a developer of therapeutic and diagnostic products primarily for disorders in the central nervous system, has announced positive data from preclinical studies of the company's regenerative therapy candidate, ALSE-100.
Subscribe to our email newsletter
The study investigated the effects of ALSE-100 on osteoblast and osteoclast cells in culture as well as in an organ culture system. ALSE-100 stimulated differentiation and mineralization to form bone nodules in culture and also inhibited bone resorption, osteoclast development and activity. These effects indicate that ALSE-100 could be useful in promoting bone healing.
Noel Cusack, senior vice president of preclinical development at Alseres, said: “We believe that this study, using a range of doses of one of our Rho inhibitor variants, ALSE-100, has demonstrated that our Rho inhibitor platform may provide potentially attractive therapeutic candidates for promoting bone healing.”